Ratings by Barclays (Eliana Merle)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/25/2026 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/17/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2026 | MBX Biosciences Inc | MBX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2026 | Regenxbio Inc. | RGNX | Downgrade | Equalweight (Overweight) |
10.50 (9.32) |
-11.24% | Details | |
| 8/7/2026 | Regenxbio Inc. | RGNX | Downgrade | Equalweight (Overweight) |
10.50 (10.50) |
0% | Details | |
| 8/6/2026 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2026 | Madrigal Pharmaceuticals | MDGL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2026 | Madrigal Pharmaceuticals | MDGL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2026 | uniQure BV | QURE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2026 | SAB Biotherapeutics | SABS | New Coverage | Overweight (N/A) |
3.87 (3.70) |
-4.39% | Details | |
| 6/22/2026 | uniQure BV | QURE | Upgrade | Overweight (Equalweight) |
46.29 (47.86) |
3.39% | Details | |
| 6/18/2026 | uniQure BV | QURE | Upgrade | Overweight (Equalweight) |
48.16 (47.86) |
-0.62% | Details | |
| 6/17/2026 | uniQure BV | QURE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/19/2026 | Gossamer Bio Inc. | GOSS | Maintain | Underweight (N/A) |
|
Details | ||
| 5/15/2026 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2026 | MBX Biosciences Inc | MBX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2026 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2026 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/1/2026 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2026 | Apellis Pharmaceuticals | APLS | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/25/2026 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/25/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/23/2026 | uniQure BV | QURE | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/10/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2026 | Regeneron Pharma | REGN | New Coverage | Overweight (N/A) |
787.50 (823.82) |
4.61% | Details | |
| 3/3/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2026 | Gossamer Bio Inc. | GOSS | Downgrade | Underweight (Overweight) |
2.13 (0.17) |
-92.02% | Details | |
| 2/23/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2026 | Tyra Biosciences | TYRA | New Coverage | Overweight (N/A) |
30.17 (25.30) |
-16.14% | Details | |
| 1/28/2026 | MBX Biosciences Inc | MBX | New Coverage | Overweight (N/A) |
36.60 (60.93) |
66.48% | Details | |
| 1/28/2026 | Regenxbio Inc. | RGNX | New Coverage | Overweight (N/A) |
13.85 (10.50) |
-24.19% | Details | |
| 1/28/2026 | uniQure BV | QURE | New Coverage | Equalweight (N/A) |
25.27 (48.16) |
90.58% | Details | |
| 1/28/2026 | Sarepta Therapeutics | SRPT | New Coverage | Equalweight (N/A) |
22.80 (21.33) |
-6.45% | Details | |
| 1/28/2026 | Moderna | MRNA | New Coverage | Equalweight (N/A) |
47.99 (154.27) |
221.46% | Details | |
| 1/28/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Equalweight (N/A) |
6.03 (10.50) |
74.13% | Details | |
| 1/28/2026 | Kymera Therapeutics | KYMR | New Coverage | Overweight (N/A) |
71.06 (119.05) |
67.53% | Details | |
| 1/28/2026 | BridgeBio Pharma | BBIO | New Coverage | Overweight (N/A) |
77.81 (76.57) |
-1.59% | Details | |
| 1/28/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Overweight (N/A) |
81.00 (59.88) |
-26.07% | Details | |
| 1/28/2026 | Apellis Pharmaceuticals | APLS | New Coverage | Equalweight (N/A) |
21.99 (41.03) |
86.58% | Details | |
| 1/28/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Overweight (N/A) |
56.78 (64.84) |
14.2% | Details | |
| 1/28/2026 | 4D Molecular Therapeutics | FDMT | New Coverage | Overweight (N/A) |
7.97 (14.35) |
80.05% | Details | |
| 1/28/2026 | Gossamer Bio Inc. | GOSS | New Coverage | Overweight (N/A) |
2.66 (2.13) |
-19.92% | Details | |
| 1/28/2026 | Ascendis Pharma | ASND | New Coverage | Overweight (N/A) |
233.65 (260.25) |
11.38% | Details | |
| 1/28/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Overweight (N/A) |
361.35 (246.11) |
-31.89% | Details | |
| 1/28/2026 | Insmed | INSM | New Coverage | Overweight (N/A) |
159.72 (121.51) |
-23.92% | Details | |
| 1/28/2026 | Inventiva SA | IVA | New Coverage | Overweight (N/A) |
7.07 (4.77) |
-32.53% | Details | |
| 1/28/2026 | Madrigal Pharmaceuticals | MDGL | New Coverage | Overweight (N/A) |
499.17 (538.71) |
7.92% | Details | |
| 1/28/2026 | Altimmune | ALT | New Coverage | Overweight (N/A) |
5.66 (3.09) |
-45.41% | Details | |
| 1/28/2026 | PTC Therapeutics | PTCT | New Coverage | Overweight (N/A) |
76.23 (70.56) |
-7.44% | Details | |
| 1/28/2026 | Vertex | VRTX | New Coverage | Overweight (N/A) |
476.84 (547.65) |
14.85% | Details |
